ArticleMolecular and cellular biochemistry2026
MELK inhibits cuproptosis in diffuse large B-cell lymphoma cells via the PI3K/mTOR/S6K-DLAT signaling axis.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With a wide range of genetic characteristics and metabolic requirements, diffuse large B-cell lymphoma (DLBCL) is an extremely complex cancer. Although maternal embryonic leucine zipper kinase (MELK) has been linked to the development of tumors, its function in DLBCL and control of cuproptosis, a copper-dependent mechanism of cell deathproduce, is yet unknown. Hub genes in DLBCL were found using integrated bioinformatic analysis of the TCGA and GEO datasets. Using qRT-PCR, WB, cell viability, Transwell, and mitochondrial assays, MELK expression was examined in DLBCL cell lines (OCI-LY8, U2932, OCI-LY7) and normal B cells (GM12878). Functional analyses were conducted in selected DLBCL cell lines (OCI-LY7 and OCI-LY8) to accurately assess the biological roles of MELK. Elesclomol (15 nM) and copper chloride (CuCl₂, 10 µM) were used to induce cuproptosis, while DLAT overexpression and S6 kinase inhibition were used to clarify signaling processes. MELK expression was considerably elevated in DLBCL tissues and cell lines (P < 0.05). In addition to inducing mitochondrial malfunction, increasing reactive oxygen species, lowering the NADH/NAD⁺ ratio, and triggering intrinsic apoptosis, MELK silencing inhibited proliferation, migration, and invasion. MELK knockdown enhanced the sensitivity of cells to elesclomol-Cu treatment, which in turn induced cuproptosis and further reduced MELK expression. Mechanistically, MELK overexpression increased cell survival, elevated dihydrolipoamide S-acetyltransferase (DLAT), and triggered the PI3K/mTOR/S6K signaling pathway. On the other hand, MELK-mediated effects on cuproptosis and intracellular copper buildup were abolished by S6K suppression or DLAT overexpression. Through the PI3K/mTOR/S6K-DLAT axis, MELK imparts resistance to cuproptosis and increases DLBCL cell survival. MELK targeting may increase copper-induced cytotoxicity, offering a possible DLBCL treatment approach.
Indexed as
Identifiers
42228272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.